Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.43 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.43 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.43 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.38 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.37 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.35 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.35 |
| ▸ | SCN9A known ✓ | Q15858 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | PNMT | P11086 | 3/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8387825 | 1.00 | TAAR1 (0.46) | TAAR1PNMTHTR2AESR1ESR2 | |
| Hydrochloric Acid SCHEMBL8388826 | 0.98 | TAAR1 (0.45) | TAAR1PNMTHTR2AESR1ESR2 | |
| Hydrochloric Acid SCHEMBL8387703 | 0.98 | TAAR1 (0.45) | TAAR1PNMTHTR2AESR1ESR2 | |
| SCHEMBL15997 | 0.98 | TAAR1 (0.48) | TAAR1PNMTHTR2AESR1ESR2 | |
| Hydrochloric Acid SCHEMBL789069 | 0.82 | TAAR1 (0.65) | TAAR1HTR2AESR1ESR2HTR2C | |
| Hydrochloric Acid SCHEMBL7921306 | 0.80 | TAAR1 (0.62) | TAAR1PNMTHTR2AHTR2CHTR2B | |
| Methylamine SCHEMBL28853108 | 0.79 | GABRA1 (0.44) | TAAR1HTR2AESR1ESR2HTR2C | |
| SCHEMBL726804 | 0.79 | TAAR1 (0.68) | TAAR1HTR2AESR1ESR2TRPA1 | |
| Hydrochloric Acid SCHEMBL5154766 | 0.79 | TAAR1 (0.50) | TAAR1HTR2AESR1ESR2HTR2C | |
| SCHEMBL2095297 | 0.78 | ESR1 (0.44) | TAAR1HTR2AESR1ESR2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113025308-B | Quantum dot film, quantum dot light-emitting diode and preparation method thereof | TCL科技集团股份有限公司 | 2023-04-07 | — | — | CN | claimed |
| WO-2021129761-A9 | QUANTUM DOT FILM, QUANTUM DOT LIGHT-EMITTING DIODE AND PREPARATION METHOD THEREOF | TCL科技集团股份有限公司 | 2021-07-29 | — | — | WO | claimed |
| WO-2021129761-A1 | QUANTUM DOT FILM, QUANTUM DOT LIGHT-EMITTING DIODE AND PREPARATION METHOD THEREOF | TCL科技集团股份有限公司 | 2021-07-01 | — | — | WO | claimed |
| CN-113025308-A | Quantum dot film, quantum dot light-emitting diode and preparation method thereof | TCL集团股份有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-107801401-B | Cleaning composition with ionic liquid | 约翰逊父子公司 | 2021-06-04 | — | — | CN | claimed |
| CN-110386988-B | Modified starch and preparation method and application thereof | 瑞辰星生物技术（广州）有限公司 | 2021-06-04 | — | — | CN | claimed |
| CN-110387761-B | Method for recovering free starch in papermaking white water | 瑞辰星生物技术（广州）有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-110387765-B | Method for making paper | 瑞辰星生物技术（广州）有限公司 | 2021-01-01 | — | — | CN | claimed |
| CN-112059202-A | Preparation method and application of silver-copper bimetallic nano-fiber | 昆明贵研新材料科技有限公司 | 2020-12-11 | — | — | CN | claimed |
| US-20170258861-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | SQUIRES MERYL J (US) | 2017-09-14 | — | — | US | claimed |
| US-20090191288-A1 | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | SQUIRES MERYL J | 2009-07-30 | — | — | US | claimed |
| US-6946490-B2 | Antimicrobial treatment for herpes simplex virus and other infectious diseases | MCGINLEY PARTNERS, LLC (US) | 2005-09-20 | — | — | US | claimed |
| EP-0980203-A4 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 2004-05-06 | — | — | EP | claimed |
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | MCGINLEY PARTNERS, LLC (US) | 2003-06-05 | — | — | US | claimed |
| US-20030099726-A1 | Antimicrobial treatment for herpes simplex virus and other infectious diseases | MCGINLEY PARTNERS, LLC (US) | 2003-05-29 | — | — | US | claimed |
| US-6355684-B1 | AQUEOUS BENZALKONIUM CHLORIDE, ECHINACEA AND ANTIMICROBIAL ISOLATES; VIRICIDES FOR PAPILLOMA, VARICELLA-ZOSTER, AND CYTOMEGALO VIRUSE; HIGH SPEED ANALGESIC; HEALING OF LESIONS; TOPICAL ADMINISTERING | Squires, Meryl J. | 2002-03-12 | — | — | US | claimed |
| EP-0980203-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | Squires, Meryl (US) | 2000-02-23 | — | — | EP | claimed |
| WO-1998042188-A1 | ANTIMICROBIAL PREVENTION AND TREATMENT OF HUMAN IMMUNEDEFICIENCY VIRUS AND OTHER INFECTIOUS DISEASES | SQUIRES MERYL (US) | 1998-10-01 | — | — | WO | claimed |
| CN-113025308-B | Quantum dot film, quantum dot light-emitting diode and preparation method thereof | TCL科技集团股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-4563483-A | FOAM WUTH SKIN HAVING METALLIC LUSTER | CREATIVE PRODUCTS RESOURCE LTD. (US) | 1986-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258861-A1 | Treatment of Herpes, Pseudomonas, Staph, and Hepatitis | NISCH, CUTA, HRH1 | HTR2A 4262/4885ESR1 4484/4885ESR2 4350/4885 |
| US-20030099726-A1 | Antimicrobial treatment for herpes simplex virus and other infectious diseases | KCNJ11, KCNJ1, TRPA1 | HTR2A 4673/4885ESR1 1194/4885ESR2 1300/4885 |
| US-20090191288-A1 | Composition to Treat Herpes, Pseudomonas, Staph, Hepatitis and Other Infectious Diseases | ASPH, KCNH3, PRPH | HTR2A 4180/4885ESR1 4531/4885ESR2 4454/4885 |
| US-20030104082-A1 | Antimicrobial prevention and treatment of human immunedeficience virus and other infectious diseases | CD14, CD59, SLC19A1 | HTR2A 4837/4885ESR1 2967/4885ESR2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.